Division of Obstetrics and Prenatal Medicine, Department of Gynecology and Obstetrics, University Hospital Frankfurt, J. W. Goethe-University, Frankfurt, Germany.
Hum Reprod Update. 2022 Nov 2;28(6):890-909. doi: 10.1093/humupd/dmac027.
The key oncogene B-cell lymphoma 6 (BCL6) drives malignant progression by promoting proliferation, overriding DNA damage checkpoints and blocking cell terminal differentiation. However, its functions in the placenta and the endometrium remain to be defined.
Recent studies provide evidence that BCL6 may play various roles in the human placenta and the endometrium. Deregulated BCL6 might be related to the pathogenesis of pre-eclampsia (PE) as well as endometriosis. In this narrative review, we aimed to summarize the current knowledge regarding the pathophysiological role of BCL6 in these two reproductive organs, discuss related molecular mechanisms, and underline associated research perspectives.
We conducted a comprehensive literature search using PubMed for human, animal and cellular studies published until October 2021 in the following areas: BCL6 in the placenta, in PE and in endometriosis, in combination with its functions in proliferation, fusion, migration, invasion, differentiation, stem/progenitor cell maintenance and lineage commitment.
The data demonstrate that BCL6 is important in cell proliferation, survival, differentiation, migration and invasion of trophoblastic cells. BCL6 may have critical roles in stem/progenitor cell survival and differentiation in the placenta and the endometrium. BCL6 is aberrantly upregulated in pre-eclamptic placentas and endometriotic lesions through various mechanisms, including changes in gene transcription and mRNA translation as well as post-transcriptional/translational modifications. Importantly, increased endometrial BCL6 is considered to be a non-invasive diagnostic marker for endometriosis and a predictor for poor outcomes of IVF. These data highlight that BCL6 is crucial for placental development and endometrium homeostasis, and its upregulation is associated with the pathogenesis of PE, endometriosis and infertility.
The lesson learned from studies of the key oncogene BCL6 reinforces the notion that numerous signaling pathways and regulators are shared by tumors and reproductive organs. Their alteration may promote the progression of malignancies as well as the development of gestational and reproductive disorders.
关键致癌基因 B 细胞淋巴瘤 6(BCL6)通过促进增殖、覆盖 DNA 损伤检查点和阻止细胞终末分化来驱动恶性进展。然而,其在胎盘和子宫内膜中的功能仍有待确定。
最近的研究提供了证据,表明 BCL6 可能在人类胎盘和子宫内膜中发挥各种作用。失调的 BCL6 可能与子痫前期(PE)和子宫内膜异位症的发病机制有关。在本叙述性综述中,我们旨在总结 BCL6 在这两个生殖器官中的病理生理作用的现有知识,讨论相关的分子机制,并强调相关的研究观点。
我们使用 PubMed 对截至 2021 年 10 月发表的人类、动物和细胞研究进行了全面的文献检索,检索的领域包括:BCL6 在胎盘、PE 和子宫内膜异位症中的作用,以及其在增殖、融合、迁移、侵袭、分化、干细胞/祖细胞维持和谱系决定中的作用。
数据表明,BCL6 对滋养细胞的增殖、存活、分化、迁移和侵袭很重要。BCL6 可能在胎盘和子宫内膜中的干细胞/祖细胞存活和分化中具有关键作用。BCL6 通过各种机制在子痫前期胎盘和子宫内膜异位症病变中异常上调,包括基因转录和 mRNA 翻译以及转录后/翻译后修饰的变化。重要的是,子宫内膜 BCL6 的增加被认为是子宫内膜异位症的非侵入性诊断标志物,也是 IVF 结局不佳的预测因子。这些数据强调了 BCL6 对胎盘发育和子宫内膜稳态的重要性,其上调与 PE、子宫内膜异位症和不孕的发病机制有关。
从关键致癌基因 BCL6 的研究中吸取的教训加强了这样一种观点,即许多信号通路和调节剂在肿瘤和生殖器官中是共有的。它们的改变可能会促进恶性肿瘤的进展以及妊娠和生殖障碍的发展。